AU2021205415B2 - Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists - Google Patents

Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists

Info

Publication number
AU2021205415B2
AU2021205415B2 AU2021205415A AU2021205415A AU2021205415B2 AU 2021205415 B2 AU2021205415 B2 AU 2021205415B2 AU 2021205415 A AU2021205415 A AU 2021205415A AU 2021205415 A AU2021205415 A AU 2021205415A AU 2021205415 B2 AU2021205415 B2 AU 2021205415B2
Authority
AU
Australia
Prior art keywords
pen
peptides
lys
glu
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021205415A
Other languages
English (en)
Other versions
AU2021205415A8 (en
AU2021205415A1 (en
Inventor
Xiaoli Cheng
Suneel Kumar Gupta
David Y. Liu
Larry C. Mattheakis
Nishit Bachulal Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protagonist Therapeutics Inc
Original Assignee
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc
Publication of AU2021205415A1 publication Critical patent/AU2021205415A1/en
Publication of AU2021205415A8 publication Critical patent/AU2021205415A8/en
Application granted granted Critical
Publication of AU2021205415B2 publication Critical patent/AU2021205415B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AU2021205415A 2020-01-10 2021-01-08 Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists Active AU2021205415B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959854P 2020-01-10 2020-01-10
US62/959,854 2020-01-10
PCT/US2021/012842 WO2021142373A1 (en) 2020-01-10 2021-01-08 METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS

Publications (3)

Publication Number Publication Date
AU2021205415A1 AU2021205415A1 (en) 2022-07-21
AU2021205415A8 AU2021205415A8 (en) 2023-08-10
AU2021205415B2 true AU2021205415B2 (en) 2026-06-04

Family

ID=76788328

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021205415A Active AU2021205415B2 (en) 2020-01-10 2021-01-08 Methods for treating inflammatory bowel diseases with α4β7 integrin antagonists

Country Status (11)

Country Link
US (1) US20230063321A1 (enExample)
EP (1) EP4093421A4 (enExample)
JP (2) JP7744910B2 (enExample)
KR (1) KR20220125268A (enExample)
AU (1) AU2021205415B2 (enExample)
BR (1) BR112022013628A2 (enExample)
CA (1) CA3166637A1 (enExample)
IL (1) IL294580A (enExample)
MX (1) MX2022008486A (enExample)
PH (1) PH12022551651A1 (enExample)
WO (1) WO2021142373A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
KR20250084325A (ko) * 2023-12-01 2025-06-11 주식회사 쓰리빅스 염증성 장질환 예방 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180148477A1 (en) * 2014-10-01 2018-05-31 Protagonist Therapeutics, Inc. NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US20190016756A1 (en) * 2014-05-16 2019-01-17 Protagonist Therapeutics, Inc. NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013011130A (es) * 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
WO2013078375A2 (en) * 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
KR20200015540A (ko) * 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190016756A1 (en) * 2014-05-16 2019-01-17 Protagonist Therapeutics, Inc. NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS
US20180148477A1 (en) * 2014-10-01 2018-05-31 Protagonist Therapeutics, Inc. NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS

Also Published As

Publication number Publication date
WO2021142373A1 (en) 2021-07-15
JP2023509790A (ja) 2023-03-09
JP7744910B2 (ja) 2025-09-26
AU2021205415A8 (en) 2023-08-10
IL294580A (en) 2022-09-01
US20230063321A1 (en) 2023-03-02
KR20220125268A (ko) 2022-09-14
PH12022551651A1 (en) 2023-11-20
CA3166637A1 (en) 2021-07-15
EP4093421A1 (en) 2022-11-30
MX2022008486A (es) 2022-10-13
CN115038457A (zh) 2022-09-09
BR112022013628A2 (pt) 2022-11-22
JP2025186365A (ja) 2025-12-23
EP4093421A4 (en) 2024-01-10
AU2021205415A1 (en) 2022-07-21

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 29 , PAGE(S) 4142 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAMES PROTAGONIST THERAPEUTICS, INC.; SUNEEL KUMAR GUPTA; NISHIT BACHULAL MODI, APPLICATION NO. 2021205415, UNDER INID (71) REMOVE CO-APPLICANTS SUNEEL KUMAR GUPTA; NISHIT BACHULAL MODI